Clinical efficacy analysis of preoperative neoadjuvant chemotherapy with high-dose dense paclitaxel plus cisplatin in Stages IB2, IIA2, IIB cervical cancer in Iran

Purpose of investigation: In Iran, the authors use neoadjuvant chemotherapy (NACT) prior to surgery in cervical cancer due to limited access to the radiotherapy and very prolonged waiting time in accession to radiotherapy. The study was done to analyze the efficacy of the NACT with high dose-dense paclitaxel and cisplatin before radical surgery on cure rate, survival rate, and the progression of free survival rate of bulky tumor of cervical cancer in Stages IB2, IId A2, and IIB. Materials and Methods: Fiftytwo patients with cervical cancer in Stages Ib2, IIA2, and IIB were selected, and responding patients to chemotherapy were scheduled to undergo radical hysterectomy and bilateral pelvic lymphadenectomy with or without para-aortic lymphadenectomy. Results: Fifty out of 52 patients with a median age of 50 years were evaluable for clinical response. Thirty-two patients (64%) responded to the NACT including six (12%) with a complete clinical response. There was no statistical relationship between clinical response, tumor stage and size, and parametrical involvement, however, patients with higher grade of tumor, adenocarcinoma or tumor in upper 2/3 of vagina showed a higher probability of no response to chemotherapy. Downstaging after NACT in all stages was statistically significant regarding pathologic findings and clinical response (p = 0.002). Five-year survival was 88% and factors affecting survival and disease-free survival were pathological response and tumor site based on cox-regression analysis. Overall recurrence rate was 20% and tumor size was the only significant relevant factor for recurrence (p = 0.017). Conclusion: Combined regimen of chemotherapy in locally advanced cervical cancer proved to be valuable and efficacious without any late complications.

Cervical cancer; Neoadjuvant chemotherapy; Radical surgery.

[1] Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., Borras J., et al.: “International trends in incidence of cervical cancer: II. Squamous-cell carcinoma”. Int. J. Cancer, 2000, 86, 429.

[2] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.

[3] Gong L., Lou J.Y., Wang P., Zhang J.W., Liu H., Peng Z.L.: “Clinical evaluation of neoadjuvant chemotherapy followed by radical surgeryin the management of stage IB2-IIB cervical cancer”. Int. J. Gynaecol. Obstet., 2012, 117, 23.

[4] Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L., 3rd., et al.: “Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma”. N. Engl. J. Med., 1999, 340, 1154.

[5] Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al.: “Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer”. N. Engl. J. Med., 1999, 340, 1137.

[6] Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al.: “Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer”. N. Engl. J. Med., 1999, 340, 1144.

[7] Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C., Jr., et al.: “Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative paraaortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study”. J. Clin. Oncol., 1999, 17, 1339.

[8] Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al.: “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)”. Eur. J. Cancer, 2009, 45, 228.

[9] Buda A., Fossati R., Colombo N., Fei F., Floriani I., Gueli Alletti D., et al.: “Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study”. J. Clin. Oncol., 2005, 23, 4137.

[10] Sardi J., Sananes C., Giaroli A., Maya G., di Paola G.: “Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri”. Gynecol. Oncol., 1990, 38, 486.

[11] Benedetti-Panici P., Greggi S., Scambia G., Amoroso M., Salerno M.G., Maneschi F., et al.: “Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer”. Eur. J. Cancer, 1998, 34, 341.

[12] Panici P.B., Scambia G., Baiocchi G., Greggi S., Ragusa G., Gallo A., et al.: “Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival”. Cancer, 1991, 67, 372.

[13] Kim D.S., Moon H., Kim K.T., Hwang Y.Y., Cho S.H., Kim S.R.: “Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor”. Gynecol. Oncol., 1989, 33, 225.

[14] Collaboration NCfLACCM-a: “Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials”. Eur. J. Cancer, 2003, 39, 2470.

[15] Singh R.B., Chander S., Mohanti B.K., Pathy S., Kumar S., Bhatla N., et al.: “Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study”. Gynecol. Oncol., 2013, 129, 124.

[16] Lissoni A.A., Colombo N., Pellegrino A., Parma G., Zola P., Katsaros D., et al.: “A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin

(TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study”. Ann. Oncol., 2009, 20, 660.

[17] Behtash N., Nazari Z., Ayatollahi H., Modarres M., Ghaemmaghami F., Mousavi A.: “Neoadjuvant chemotherapy and radical surgery compared to radical surgery alone in bulky stage IB-IIA cervical cancer”. Eur. J. Surg. Oncol., 2006, 32, 1226.

[18] Dueñas-Gonzalez A., López-Graniel C., González-Enciso A., Cetina L., Rivera L., Mariscal I., et al.: “A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation”. Ann. Oncol., 2003, 14, 1278.

[19] Chang T.C., Lai C.H., Hong J.H., Hsueh S., Huang K.G., Chou H.H., et al.: “Randomized trial of neoadjuvant cisplatin, vincristine,bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer”. J. Clin. Oncol., 2000, 18, 1740.

[20] Hwang Y.Y., Moon H., Cho S.H., Kim K.T., Moon Y.J., Kim S.R., etal.: “Ten- year survival of patients with locally advanced, stage ib-iib cervical cancer after neoadjuvant chemotherapy and radical hysterectomy”.Gynecol. Oncol., 2001, 82, 88.